Podcasts about ebmt

In this week's VJHemOnc podcast, we'll be sharing highlights from the 51st Annual Meeting of the EBMT, with a focus... The post Highlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & more appeared first on VJHemOnc.

Timestamps:      00:00- Introduction  00:41- Health benefits of yoga and mindfulness   02:34- The potential of AI in hematology  04:23- Transfusion dependence in myelodysplastic syndromes  08:13- The fascinating field of apheresis  10:56- How to provide high-quality, affordable healthcare?  15:44- Regulatory T cells in hematologic malignancies  19:55- CAR T clinical trials: regulatory insights  22:57- EBMT initiatives  30:06- Latest breakthroughs in amyloidosis   34:50- Reducing patient fear through education 

When we talk about myelin damage, most of us typically think of the brain. After all, that myelin is located in your central nervous system. But the inflammation that causes myelin damage may be triggered by activity that's taking place well south of your central nervous system, in your gut microbiome, the colony of trillions of bacteria and microorganisms that live in your intestines.  Dr. Ashutosh Mangalam joins me to help us understand what this gut-brain connection is all about, how that connection impacts MS, and what you can do to change the makeup of your gut microbiome. Dr. Mangalam is an Associate Professor of Pathology at the Carver College of Medicine at the University of Iowa, where his research is focused on studying the gut microbiome and the immune system in multiple sclerosis. We're also talking about the newly published guidance from the European Committee for Treatment and Research in MS and the European Society for Blood and Marrow Transplantation, recommending autologous hematopoietic stem cell transplantation (aHSCT) for treating some cases of relapsing-remitting MS. We'll tell you about an experimental drug that may resolve MS-related vision issues through remyelination.  And we'll introduce you to this year's winner of the Barancik Prize for Innovation in MS Research. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: The gut-brain connection (and what it means if you're liviing with MS)  :22 The European Committee for Treatment and Research in MS and the European Society for Blood and Marrow Transplantation issue a recommendation for stem cell therapy to treat relapsing-remitting MS  1:35 Researchers develop a drug that may resolve MS-related vision issues through remyelination  4:44 National MS Society names this year's winner of the Barancik Prize for Innovation in MS Research  7:23 Dr. Ashutosh Mangalam explains how (and why) the brain-gut connection impacts MS    11:14 Share this episode  35:38 Have you downloaded the free RealTalk MS app?  35:58 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/388 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com RealTalk MS on YouTube https://www.youtube.com/@RealTalkMS Autologous Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder -- Recommendations from ECTRIMS and EBMT https://www.nature.com/articles/s41582-024-01050-x National MS Society Releases Recommendations for aHSCT-Bone Marrow Transplant for MS https://nationalmssociety.org/news-and-magazine/news/national-ms-society-releases-recommendations STUDY: Incomplete Remyelination Via Therapeutically Enhanced Oligodendrogenesis Is Sufficient to Recover Visual Cortical Functionhttps://www.nature.com/articles/s41467-025-56092-6 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 388 Guest: Dr. Ashutosh Mangalam Privacy Policy

This week, Jonathan is joined by Anna Sureda, Head of the Clinical Hematology Department at Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain, and President of the European Society for Blood and Marrow Transplantation (EBMT) Association, to discuss the latest in lymphoma therapies and stem cell transplantation. Timestamps:     (00:00)-Introduction  (01:48)-Memorable travels  (07:44)-Sureda's journey into hematology   (12:40)-Breakthroughs in lymphoma treatment   (17:54)-Advances in stem cell transplantation   (20:26)-EBMT initiatives  (29:17)-Allogeneic transplantation for T cell lymphomas  (34:32)-Challenges in treatment accessibility   (41:35)-How can we ensure health equity?  (46:00)-Advice to young hematologists   (47:40)-Sureda's three wishes for healthcare 

In this JCO Article Insights episode, Alexandra Rojek provides a summary on "Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors" by Schaffer et al published in the Journal of Clinical Oncology July 17th, 2024. TRANSCRIPT Alexandra Rojek: Hello and welcome to JCO Article Insights. I'm your host, Alexandra Rojek, and today we will be discussing an original report published in the October 1st issue of JCO titled, “Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors,” by Shaffer et al. The CIBMTR registry study set out to compare outcomes of patients undergoing allogeneic stem cell transplantation hematologic malignancies by HLA antigen matching status as well as by the type of GVHD prophylaxis regimen received either calcineurin inhibitor-based prophylaxis or post-transplant cyclophosphamide or PTCy. This study included patients reported to CIBMTR from January 2017 to June 2021 with AML, ALL or MDS, and required that they have undergone allotransplant with either a calcineurin inhibitor based so tacro or cyclosporine, GVHD prophylaxis, or PTCy, which included a calcineurin inhibitor or sirolimus with or without MMF and ATG. Matched unrelated donors were defined as an 8 out of 8 HLA match. And mismatched unrelated donors were defined as HLA mismatched at any single locus or 7 out of 8. The primary objective of the study aimed to compare overall survival or OS and GVHD and relapse-free survival (GRFS) within and between matched unrelated donors versus mismatched unrelated donors separated by calcineurin inhibitor versus PTCy based GVHD prophylaxis. GRFS was defined as survival without grade 3 to 4 acute GVHD, moderate to severe chronic GVHD requiring systemic therapy or relapse. 10,025 patients were included from 153 centers, with a median follow up of over 36 months. Mismatched unrelated donor recipients were made up of 22% minority ancestry patients as compared to just 8% of patients receiving a matched unrelated donor allo transplant, showing an enrichment for patients of minority ancestry in the mismatched unrelated donor group. Just under 10% of patients were of minority ancestry in the study overall, reflective of challenges in transplant care for these patients, which may include inferior access to care, fewer available and suitably matched donors, among other factors. 54% of all patients were transplanted for AML and 29% for MDS. 45% of patients received myeloablative conditioning, 25% received regimens containing ATG, and 23% overall received PTCy with either a calcineurin inhibitor or sirolimus as well as MMF. Among patients receiving PTCy, the authors did not find differences in overall survival by degree of HLA matching, whereas among patients receiving calcineurin inhibitor-based prophylaxis, there remained survival differences by HLA matching status. When comparing matched unrelated donor calcineurin inhibitor patients with PTCy matched unrelated donor patients, the PTCy arm had better OS, and the mismatched unrelated donor group who received PTCy had similar OS as well. For GRFS, matched unrelated donor and mismatched unrelated donor PTCy patients had no difference in GRFS, similar to the trend the authors see with overall survival. But these patients also had better GRFS than matched unrelated donor patients receiving calcineurin inhibitor-based prophylaxis. Within each prophylaxis arm, there was no difference in GRFS by HLA matching status. HLA mismatched patients receiving PTCy were less likely to experience GRFS than HLA mismatched patients receiving calcineurin inhibitor-based prophylaxis. The authors saw similar differences in comparative trends when subgrouping patients based on conditioning intensity and additionally did not find differences in GRFS and OS by ATG exposure. When looking at patients with minority ancestry, those patients who received a match unrelated donor or mismatched unrelated donor with PTCy had comparable outcomes to non-Hispanic white patients. Additionally, among minority ancestry patients, there was a significant benefit in both GRFS and OS in the PTCy groups as compared to calcineurin inhibitor-based prophylaxis. When examining other specific toxicities included in the composite GRFS endpoint, such as GVHD rates among PTCy patients, the authors note that patients receiving a matched unrelated donor had similar rates of grade 3 to 4 acute GVHD but lower rates of moderate to severe chronic GVHD requiring systemic therapy. There appears to be signal that among PTCy patients, HLA matching reduced rates of moderate to severe chronic GVHD compared to mismatched unrelated donor patients receiving PTCy. These same trends also held when the authors looked at non relapse mortality with no significant differences within the PTCy groups by HLA matching status but reduced non relapse mortality compared to both calcineur and inhibitor-based groups. However, notably, there was a greater risk of relapse among matched unrelated donor PTCy patients than matched unrelated donor calcineurin inhibitor patients, although this risk was comparable between mismatched unrelated donor patients by type of prophylaxis. The authors note that this has also been observed in other retrospective cohorts and may be confounded by differences in conditioning intensity between these cohorts of matched unrelated donor patients, affecting the risk of relapse. Finally, the authors also evaluate whether expansion of donor search criteria to mismatch donors from full HLA matching would increase availability of young donors from minority ancestry patients, and the study noted striking increases for all subgroups examined. This study fits nicely with the BMT CTN 1703 trial published in the recent past, which has showed the superiority of PTCy with the calcineurin inhibitor and MMF when compared with conventional calcineurin inhibitor based immune prophylaxis for reduced intensity matched related donor and matched unrelated donor allotransplant. Of note, very few patients with one HLA antigen mismatch were enrolled on that study. However, others have shown the feasibility of PTCy in the mismatched unrelated donor setting, which has led to its adoption in practice. Although less than a quarter of patients included in this current study received PTCy overall, the findings clearly are aligned with the BMT CTN 1703 study, which is likely to change clinical practice in the longer term in this field. As the accompanying editorial in JCO, written by Dr. Chakravarty nicely lays out, the differences between this study and the EBMT registry study, also published in this issue of JCO are subtle but worthy of note. While both studies show that mismatched unrelated donor patients had worse OS and GRFS than those receiving matched unrelated donor transplants, and then among matched unrelated donor patients the addition of PTCy improved GRFS and OS, there is discordance between the studies whether the addition of PTCy abrogates the effect of HLA mismatching on GRFS and OS. As this editorial points out, there are strikingly different rates of T cell depletion with ATG between the US and Europe, which may account for differences in comparator arms that lead to this discordance. There are several very exciting clinical trials ongoing that will aim to answer some of these outstanding questions regarding comparisons of PTCy and T cell depletion, which the field eagerly looks forward to reviewing. In summary, this registry study of patients receiving allo transplant with matched unrelated donor or mismatched unrelated donor and calcineurin inhibitor or PTCy based GVHD prophylaxis, most notably shows that for patients who may not have a matched unrelated donor available, the addition of PTCy to a mismatched unrelated donor allo transplant allows for improved outcomes after transplant in toxicities and survival. This is most significant for patients of minority ancestries who usually have fewer matched unrelated donors available in registry searches. Improving the transplant options available to these groups of patients is of critical importance in improving equitable access to care for all of our patients. And this study, although retrospective in nature, provides an important understanding of our progress to date and suggests directions for future investigation may indeed be very feasible to continue to close these gaps in care for patients in need of an allo transplant for hematologic malignancies. This is Alexandra Rojek. Thank you for listening to JCO Article Insights. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

Graft-versus-host disease (GvHD) is a common complication following allogeneic stem cell transplantation (alloSCT), which is typically classified as acute or... The post Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome appeared first on VJHemOnc.

OMG! In this extra fun holiday episode, we are joined by lymphoma experts Tycel Phillips and Aaron Goodman to review the most impactful and controversial lymphoma abstracts from ASH! Stay tuned for a lively discussion! Abstracts Discussed! SYMPATICO (Ibrutinib + Ven in R/R MCL): https://ash.confex.com/ash/2023/webprogram/Paper191921.html Nivo-AVD in elderly Hodgkin Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper180114.html BOVEN - Zanubrutinib + Obi + Ven in TP53 mutant MCL: https://ash.confex.com/ash/2023/webprogram/Paper180069.html CAR-T in CNS Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper174883.html (EBMT data), https://ash.confex.com/ash/2023/webprogram/Paper184345.html (Multicenter retrospective study) Synthetic Control Arms: https://ash.confex.com/ash/2023/webprogram/Paper177708.html POLARIX Subgroup Analysis (shout out to the Blood Cancer Talks crew!): https://x.com/Eddie_Cliff/status/1733901400822993257?s=20

Wir berichten vom Europäischen Hämatologiekongress, EHA. In Frankfurt haben wir u.a. mit Dr. Kai Rejeski von der LMU München gesprochen über aktuelle Empfehlungen der EHA und EBMT für „Immune effector cell-associated hematotoxicity“ (ICAHT), also hämatologische Nebenwirkungen, die unter CAR-T-Zell-Therapie auftreten. Zudem gibt es aktuelle Daten zum Sechs-Jahres-Update der CLL14-Studie mit Venetoclax /Obinutuzumab bei chronischer lymphatischer Leukämie von Dr. Othman Al-Sawaf, Uniklinik Köln. Weitere Themen der Folge: Wie das Mikrobiom die Wirksamkeit von Therapien beeinflussen kann und welche Rolle dabei eine Antibiose spielt. Zudem diskutieren wir, welche neuen Optionen für das transfusionsabhängige Myelodysplastische Syndrom (MDS) mit niedrigem Risiko in der Pipeline stehen. So könnte bald in der Erstlinie Luspatercept und in der Zweitlinie Imetelstat zugelassen werden. Denn bei einigen Patient:innen führen sie zu anhaltender Transfusionsfreiheit. Komplette Berichterstattung vom EHA: www.medical-tribune.de/eha-2023 Publikation zu ICAHT: https://ashpublications.org/blood/article/doi/10.1182/blood.2023020578/496185/Immune-Effector-Cell-Associated-Hematotoxicity Abstract CLL14-Studie: https://library.ehaweb.org/eha/2022/eha2022-congress/357012/othman.al-sawaf.venetoclax-obinutuzumab.for.previously.untreated.chronic.html

The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), which took place on 19-23 March... The post Impact of the COVID-19 pandemic on the EBMT & projects in the pipeline appeared first on VJHemOnc.

The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), which took place on 19-23 March... The post Impact of the COVID-19 pandemic on the EBMT & projects in the pipeline appeared first on VJHemOnc.

Anna Sureda is president elect of EBMT

Progression and persistence of malignancies are influenced by the local tumor microenvironment, and future eradication of currently incurable tumors will, in part, hinge on our understanding of malignant cell biology in the context of their nourishing surroundings. Article: https://www.nature.com/articles/s41590-021-00931-3 CONNECT with Trainee Committee https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee CONNECT with Madelon https://twitter.com/maadulon MORE about EBMT https://www.ebmt.org/ https://twitter.com/TheEBMT

The following is a conversation with Robert Panza, former policeman from California and volunteer stem cell courier for the National Marrow Donor Program in the United States. We talk about the National Marrow Donor Program, how Robert got into being a stem cell courier, what it means, funny and sad stories, challenges and wonders since the pandemic. Interview: Nico Gagelmann (https://twitter.com/NicoGagelmann) MORE about our Trainee Committee on https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee MORE about EBMT on https://www.ebmt.org/ https://twitter.com/TheEBMT Robert Panza is also one of about 200 people across the USA who are volunteer NMDP Ambassadors, advocating on behalf of cellular therapy patients and the NMDP with elected officials. Wherever you are, please register as a donor to further reduce the current inequalities of donor access. Go visit the https://network.bethematchclinical.org/ https://bethematch.org/ https://www.anthonynolan.org/ https://www.dkms.org/ More on being a courier in COVID times https://twitter.com/i/status/1324440879902371841

Bronwen Shaw is MD and Professor at the Froedtert and the Medical College of Wisconsin and the current president of the World Marrow Donor Association (WMDA), which is made up of organisations and individuals who promote global collaboration and best practices for the benefit of stem cell donors and transplant patients. WMDA was informally initiated in 1988 by three pioneers in the field of transplantation: John Goldman (United Kingdom), E. Donnall Thomas (United States) and Jon J. van Rood (the Netherlands). This led to the foundation of WMDA in 1994. In 2007, WMDA became one of the founding members of the Worldwide Network for Blood and Marrow Transplantation (WBMT). WBMT is a non-profit scientific organisation which aims to promote excellence in stem cell transplantation, donation and cellular therapy. It has an official relationship with the World Health Organization. The other three founding organisations of the WBMT are the European Society for Blood and Marrow Transplantation (EBMT), the Center for International Blood & Marrow Transplant Research (CIBMTR), and the Asian Pacific Blood and Marrow Transplantation Group (APBMT). Interview: Nico Gagelmann MORE about our Trainee Committee on https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee MORE about EBMT on https://www.ebmt.org/ https://twitter.com/TheEBMT MORE about the WMDA on h ttps://wmda.info/ https://twitter.com/WMDA_office

The European Group for Blood and Marrow Transplantation (EBMT) Trainee Committee was established in 2021 to address the needs of... The post The Post-EBMT for Trainees VJSessions appeared first on VJHemOnc.

The European Group for Blood and Marrow Transplantation (EBMT) Trainee Committee was established in 2021 to address the needs of... The post The Post-EBMT for Trainees VJSessions appeared first on VJHemOnc.

The 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held virtually this year and... The post The Post-EBMT VJSessions from VJHemOnc appeared first on VJHemOnc.

The 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held virtually this year and... The post The Post-EBMT VJSessions from VJHemOnc appeared first on VJHemOnc.

Acute myeloid leukemia (AML) is the most common type of adult leukemia, with over 19,500 new cases estimated to be... The post Post-EBMT highlights in acute myeloid leukemia appeared first on VJHemOnc.

Acute myeloid leukemia (AML) is the most common type of adult leukemia, with over 19,500 new cases estimated to be... The post Post-EBMT highlights in acute myeloid leukemia appeared first on VJHemOnc.

The 3rd European CAR T-cell Meeting, organized by the European Society for Blood and Marrow Transplantation (EBMT), and the European... The post VJSession: EBMT/EHA CAR-T Nursing Session appeared first on VJHemOnc.

The 3rd European CAR T-cell Meeting, organized by the European Society for Blood and Marrow Transplantation (EBMT), and the European... The post VJSession: EBMT/EHA CAR-T Nursing Session appeared first on VJHemOnc.

Gösta Gahrton reflecting on the beginnings and evolution of EBMT.

Gösta Gahrton is Professor of Medicine at Department of Medicine, Huddinge, Karolinska Institute, Sweden. He was Head of Hematology at Huddinge Hospital and Head of the Department of Medicine Karolinska Institutet, where he established one of the first bone marrow transplantation centers. Prof Gahrton has been a member and chairman of the Nobel Committee of the Karolinska Institutet.

2001年，苏州，一个19岁刚出头的小姑娘，躺在病床上，双眼盯着电视机。她叫陈霞。此时，她手臂上、腿上插满各式各样的管子，身上没有丝毫免疫能力。电视里，正在播出的是一场长达20个小时的“带命”直播。这份造干细胞跨越两岸三地，最终目的地，是她的体内。陈霞，是苏州大学第一附属医院血液科主任吴德沛教授治疗过的万千血液病患者之一；但她又是极为特别的一个。顽强的生命力，让她仅用半年，就从白血病病情中完全康复；感恩的心，让她多年来一直亲切地称呼吴德沛教授为“吴爸爸”。她的故事曾在世纪之初，牵动无数全球华人的心弦；而在康复之后，截至今天她已经花了近20年时间，去走一条“感恩之路”。她希望用被救赎的生命，用自己抗击疾病的亲身经历，去帮助、温暖其他血液疾病患者，“反哺更多生命”。今天，我们邀请吴德沛教授和陈霞一起，讲讲那个关于生命、关于大爱的故事。吴德沛简介吴德沛，血液病学博士，国家级重点学科——苏州大学附属第一医院血液病学科主要学术带头人之一，现任苏州大学附属第一医院血液科主任，主任医师，内科血液学教授，博士生导师。吴德沛教授是江苏省“135工程”优秀医学重点人才，江苏省医学领军人才，江苏省人事厅“六大高峰”人才，省知工委“333工程”培养对象，江苏省有突出贡献的中青年专家，享受国务院特殊津贴专家，全国优秀科技工作者，江苏省优秀科技工作者及江苏省先进工作者。曾获重要科研奖励23项。吴德沛从事临床工作31年，聚焦血液病诊疗关键环节，创建骨髓移植“苏州模式”，成功开展造血干细胞移植1189例。科室累计移植4000余例，获国际骨髓移植最高奖项—“圣安东尼-EBMT”成就奖。建立中国血液病临床医学研究网络，推动中华骨髓库的迅速扩容。陈霞简介陈霞，陈霞慈善会创立者，苏州陈霞爱心慈善基金会理事长。2020年8月，在第五届“江苏慈善奖”决定中，陈霞获得优秀慈善工作者称号。2000年9月，年仅19岁的她身患急性粒细胞白血病，历经恐惧和病痛折磨后，凭坚强的意志勇敢地和病魔作斗争。2001年6月，在吴德沛教授的积极联络和帮助下，陈霞在台湾慈济骨髓库找到了与她相配的骨髓。多家电视台对该样本辗转两岸三地、来到苏州的全过程，进行了“生命二十小时——两岸拯救陈霞行动全程直播”。这是中国大陆接受的第一例来自台湾的配型成功的样本。康复后，陈霞一直进行血液病公益事业，用乐观和坚强感染每一个急需关爱和帮助的人。

2001年，苏州，一个19岁刚出头的小姑娘，躺在病床上，双眼盯着电视机。她叫陈霞。此时，她手臂上、腿上插满各式各样的管子，身上没有丝毫免疫能力。电视里，正在播出的是一场长达20个小时的“带命”直播。这份造干细胞跨越两岸三地，最终目的地，是她的体内。陈霞，是苏州大学第一附属医院血液科主任吴德沛教授治疗过的万千血液病患者之一；但她又是极为特别的一个。顽强的生命力，让她仅用半年，就从白血病病情中完全康复；感恩的心，让她多年来一直亲切地称呼吴德沛教授为“吴爸爸”。她的故事曾在世纪之初，牵动无数全球华人的心弦；而在康复之后，截至今天她已经花了近20年时间，去走一条“感恩之路”。她希望用被救赎的生命，用自己抗击疾病的亲身经历，去帮助、温暖其他血液疾病患者，“反哺更多生命”。今天，我们邀请吴德沛教授和陈霞一起，讲讲那个关于生命、关于大爱的故事。吴德沛简介吴德沛，血液病学博士，国家级重点学科——苏州大学附属第一医院血液病学科主要学术带头人之一，现任苏州大学附属第一医院血液科主任，主任医师，内科血液学教授，博士生导师。吴德沛教授是江苏省“135工程”优秀医学重点人才，江苏省医学领军人才，江苏省人事厅“六大高峰”人才，省知工委“333工程”培养对象，江苏省有突出贡献的中青年专家，享受国务院特殊津贴专家，全国优秀科技工作者，江苏省优秀科技工作者及江苏省先进工作者。曾获重要科研奖励23项。吴德沛从事临床工作31年，聚焦血液病诊疗关键环节，创建骨髓移植“苏州模式”，成功开展造血干细胞移植1189例。科室累计移植4000余例，获国际骨髓移植最高奖项—“圣安东尼-EBMT”成就奖。建立中国血液病临床医学研究网络，推动中华骨髓库的迅速扩容。陈霞简介陈霞，陈霞慈善会创立者，苏州陈霞爱心慈善基金会理事长。2020年8月，在第五届“江苏慈善奖”决定中，陈霞获得优秀慈善工作者称号。2000年9月，年仅19岁的她身患急性粒细胞白血病，历经恐惧和病痛折磨后，凭坚强的意志勇敢地和病魔作斗争。2001年6月，在吴德沛教授的积极联络和帮助下，陈霞在台湾慈济骨髓库找到了与她相配的骨髓。多家电视台对该样本辗转两岸三地、来到苏州的全过程，进行了“生命二十小时——两岸拯救陈霞行动全程直播”。这是中国大陆接受的第一例来自台湾的配型成功的样本。康复后，陈霞一直进行血液病公益事业，用乐观和坚强感染每一个急需关爱和帮助的人。

说起来也许你不愿意承认，但很多人对重大疾病的认识，都是从偶像剧来的。比如说70年代的那部日剧《血疑》，让白血病在一代人心中留下是深深的阴影。很多人看了女主幸子的遭遇，都觉得白血病是“最可怕的癌症”，而且这个观念至今难忘。电视剧《血疑》但一看日历，现在已经是2020年了，白血病到底还有没有那么可怕呢？今天，我们邀请到苏州大学第一附属医院血液科主任，从《血疑》电视剧上映那会儿，就开始治疗血液病的著名专家吴德沛教授，给大家掰开了、揉碎了聊聊，白血病以及造血干细胞移植到底是怎么一回事儿。为啥白血病在各种疾病中被比喻为“老虎”？为啥儿童多发急性淋巴细胞白血病，但治疗效果又很好？药物治疗和造血干细胞移植，二者到底怎么选？在白血病治疗中，什么叫“细胞吃细胞，细胞治细胞”？为啥有些女性康复患者的血液里会有男性的性染色体？为啥会把人体比喻为“一口井”？为啥苏州大学第一附属医院要专门开设一个“一日病房”？关于白血病的各种你知道或不知道的知识，我们有请从医经验长达42年的吴德沛教授，为我们妙语连珠，一一解密！吴德沛简介血液病学博士，苏州大学附属第一医院血液科主任，主任医师，内科血液学教授，博士生导师，国家级重点学科——苏州大学附属第一医院血液病学科主要学术带头人之一。吴德沛从事临床工作31年，成功开展造血干细胞移植1189例，科室累计移植4000余例，获国际造血干细胞移植最高奖项——“圣安东尼-EBMT”成就奖。建立中国血液病临床医学研究网络，推动中华骨髓库的迅速扩容。吴德沛教授在录制现场

说起来也许你不愿意承认，但很多人对重大疾病的认识，都是从偶像剧来的。比如说70年代的那部日剧《血疑》，让白血病在一代人心中留下是深深的阴影。很多人看了女主幸子的遭遇，都觉得白血病是“最可怕的癌症”，而且这个观念至今难忘。电视剧《血疑》但一看日历，现在已经是2020年了，白血病到底还有没有那么可怕呢？今天，我们邀请到苏州大学第一附属医院血液科主任，从《血疑》电视剧上映那会儿，就开始治疗血液病的著名专家吴德沛教授，给大家掰开了、揉碎了聊聊，白血病以及造血干细胞移植到底是怎么一回事儿。为啥白血病在各种疾病中被比喻为“老虎”？为啥儿童多发急性淋巴细胞白血病，但治疗效果又很好？药物治疗和造血干细胞移植，二者到底怎么选？在白血病治疗中，什么叫“细胞吃细胞，细胞治细胞”？为啥有些女性康复患者的血液里会有男性的性染色体？为啥会把人体比喻为“一口井”？为啥苏州大学第一附属医院要专门开设一个“一日病房”？关于白血病的各种你知道或不知道的知识，我们有请从医经验长达42年的吴德沛教授，为我们妙语连珠，一一解密！吴德沛简介血液病学博士，苏州大学附属第一医院血液科主任，主任医师，内科血液学教授，博士生导师，国家级重点学科——苏州大学附属第一医院血液病学科主要学术带头人之一。吴德沛从事临床工作31年，成功开展造血干细胞移植1189例，科室累计移植4000余例，获国际造血干细胞移植最高奖项——“圣安东尼-EBMT”成就奖。建立中国血液病临床医学研究网络，推动中华骨髓库的迅速扩容。吴德沛教授在录制现场

Cell therapy involves the transplantation of viable cells into a patient in order to trigger a medicinal effect. CAR-T is... The post Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells appeared first on VJHemOnc.

Cell therapy involves the transplantation of viable cells into a patient in order to trigger a medicinal effect. CAR-T is... The post Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells appeared first on VJHemOnc.

Hematopoietic stem cell transplantation (HSCT) is used as a treatment option for a wide variety of hematological disorders. Graft-versus-host disease... The post Latest transplant updates from EBMT 2020 appeared first on VJHemOnc.

Prof Richardson (Dana-Farber Cancer Institute, Boston, USA) talks to Prof Mohty (President of the European society for Blood and Marrrow Transplantation - EBMT) at this year's EBMT conference in Valencia, Spain, reviewing the conference highlights. With specific regard to myeloma, novel drugs including ibrutinib, carfilzomib, ixazomib, and the FDA approval of defibrotide to treat veno-occlusive disease (VOD), show great promise in reducing toxicity and increasing maintenance of patient survival. Cellular therapies and faecal transplantation are other novel techniques discussed at the conference, with notably reduced complications compared to current cytotoxic treatments Looking forward, the potential of chemotherapy-free treatment, a growing understanding of the microbiome and reducing the risk of secondary malignancies are fields of interest in the near future.

Dr Ocio, Universidad de Salamanca, Spain, speaks with ecancertv at EBMT in Valencia, Spain, reviewing the years developments in myeloma treatment, and looking forward to paths for future development in treatment constellations. Second generation proteasome inhibitors and acetylase inhibitors are among the novel drugs showing clinical promise, and autologous stem cell transplant continues to be effective in frontline and relapsed myeloma treatment.

In this podcast I had the pleasure to chat with Dave West, Product Owner & CEO for scrum.org. After discussing his road towards becoming a Product Owner (which includes a well known three letter acronym), we go in to the three most important things a Product Owner should master. Along the ride we gain insights […]

**CHECK OUT www.britanniawrestling.co.uk and "Britannia Wrestling Promotions" on Facebook!****CAUTION! Strong Language!**BWP head referee Max Davies and BWP head of production and social media Chris Dutton return for an all-new season of Encore Radio!This week, we run down all the results and happenings from The El Bandito Memorial Tournament at Denbigh Town Hall Wales, giving in-depth analysis and thoughts on every match throughout the tournament! As if that wasn't already enough, we are then joined by 2017 EBMT winner DRILL for an impromptu interview! Aren't you lucky?! A fun show as always so check it out~!(Remember as always to stick around until after the closing theme for the gag reel! Not for the easily offended!)**CHECK OUT THE 2017 EL BANDITO MEMORIAL TOURNAMENT ON THE BWP NETWORK!**https://vod.yourfightsite.com/channels/britannia-wrestling-promotionsAlso available on...iTunes - Search "BWP Encore! Radio"YouTube - https://youtu.be/Guj5xWz2yRsFacebook - http://www.facebook.com/bwpencore

**CHECK OUT www.britanniawrestling.co.uk and "Britannia Wrestling Promotions" on Facebook!** **CAUTION! Strong Language!** BWP head referee Max Davies and BWP head of production and social media Chris Dutton return for an all-new season of Encore Radio! This week, we run down all the results and happenings from The El Bandito Memorial Tournament at Denbigh Town Hall Wales, giving in-depth analysis and thoughts on every match throughout the tournament! As if that wasn't already enough, we are then joined by 2017 EBMT winner DRILL for an impromptu interview! Aren't you lucky?! A fun show as always so check it out~! (Remember as always to stick around until after the closing theme for the gag reel! Not for the easily offended!) **CHECK OUT THE 2017 EL BANDITO MEMORIAL TOURNAMENT ON THE BWP NETWORK!** https://vod.yourfightsite.com/channels/britannia-wrestling-promotions Also available on... iTunes - Search "BWP Encore! Radio" YouTube - https://youtu.be/Guj5xWz2yRs Facebook - http://www.facebook.com/bwpencore

This is a commentary on a report from the EBMT demonstrating a higher relapse rate after allogeneic transplantation in AML patients with FLT3 ITD mutations.

Hintergrund: Patienten nach HSZT haben ein ansteigendes Risiko erneut an malignen Zweittumoren zu erkranken. Die Häufigkeit und Risikofaktoren für maligne Zeittumore bei Langzeitüberlebenden wurden in dieser retrospektiven Multicenter-follow-up-Studie berechnet. In der bereits 1999 vorgenommenen Analyse dieser 1036 Patienten aus 45 Transplantationszentren der EBMT, welche mehr als 5 Jahre nach Transplantation überlebten, galten Patientenalter und Immunsuppression als Hauptrisikofaktoren für die Entstehung von malignen Zweittumoren. Patienten und Methoden: In der aktuellen Follow-up Studie konnten Daten von 636 Patienten erneut erhoben werden, 100 Patienten starben und von 300 Patienten konnten die Daten nicht aktualisiert werden. Erneut wurden Zweittumore erfragt, die kumulative Inzidenz ermittelt und einer Vergleichsgruppe nach Alter und Geschlecht gegenübergestellt. Als Variablen wurden Patientenalter und –geschlecht, Diagnose und Krankheitszustand zum Zeitpunkt der Transplantation, Histokompatibilität des Spenders, Konditionierungsschemata, Prophylaxe, Entwicklung und Therapie einer Graft versus Host-Erkrankung geprüft. Mit Hilfe des Log Rank Testes wurden in der Univariaten Analyse potenzielle Risikofaktoren für maligne Zweittumore mit der Zeit bis zur Tumordiagnose ermittelt. Risikofaktoren mit p < 0,200 wurden in die Multivariate Analyse (Cox Regression) einbezogen. Ergebnisse: Die mediane Beobachtungszeit nach Transplantation lag bei 17,9 Jahren. Zweittumore wurden bei 114 Patienten erfasst, das errechnete Risiko für einen malignen Zweittumor betrug nach 10 Jahren 4,0% nach 15 Jahren 8,5%, nach 20 Jahren 14% und nach 25 Jahren 21%.Die Inzidenz für maligne Tumore in dieser Patientengruppe war ca. 6-mal höher als in einer nach Alter und Geschlecht geordneten Vergleichsgruppe (p < 0,001).Als Risikofaktoren nach HSZT ergaben sich in der multivariaten Analyse Patientenalter > 30 Jahre (HR 1,022; 95% KI 1,003-1,0042; p = 0,025) und immunsuppressive Behandlung (HR 3,223; KI 1,168-8,899; p = 0,024), speziell mit Thalidomid. Tumorfreies Überleben reduziert sich bei Patienten älter als 30 Jahre bei Transplantation (HR 1,032; KI 1,019-1,046;48 p < 0,001), bei Patienten, die einen weiblichen Stammzellspender haben (HR 1,426; KI 1,052-1,931; p = 0,022), immunsuppressiver Behandlung (HR 1,441; KI 1,060-1,957; p = 2,020) und Strahlentherapie (HR 1,986; KI 1,067-3,696; p = 0,030). Schlussfolgerung: Eine längere Nachbeobachtung von Patienten nach HSZT zeigt einen übernormalen Anstieg der kumulativen Inzidenz für maligne Neubildungen. Eine Nachbeobachtungszeit von mehr als 15 Jahren beweist, dass nicht nur älteres Patientenalter und Immunsuppression, sondern auch weibliches Spendergeschlecht und Strahlentherapie Risikofaktoren für ein Überleben ohne Zweitmalignome sind.